ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks
- Category: Antibodies
- Published on Friday, 18 September 2020 10:36
- Hits: 2422
VICTORIA, Canada I September 17, 2020 I IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, announce a research collaboration with Zymeworks Inc., giving ImmunoPrecise access to Zymeworks' Azymetric™ and EFECT™ platforms for the further development of its multiple antibody candidates to fight COVID-19.
Under the terms of the agreement, IPA will transform its previously tested and potent SARS-CoV-2 neutralizing antibodies into bispecific and multispecific antibodies using the Zymeworks' platforms. These sets of candidates will be thoroughly tested using SARS-CoV-2 spike protein provided by the National Research Council Canada ("NRC"), prior to pre-clinical manufacturing at the NRC for animal studies. Timelines for the Companies pre-clinical studies examining the efficacy of IPA's Polytope therapies using traditional antibody formats are not impacted by these additional investigations into formulation.
"Global health issues like the COVID-19 pandemic represent significant times for companies like IPA to share our collective expertise and technologies to bring forward safe and efficacious therapies," said Ali Tehrani, Ph.D., President and CEO of Zymeworks. "We look forward to continuing our relationship with ImmunoPrecise as they advance multi-specific candidates toward the clinic."
"After the discovery of potently neutralizing antibodies in a combinatorial setting, it was a logical consequence for us to look into clinically-proven, multi-specific antibody platforms," said Jennifer Bath, Ph.D., President and CEO of ImmunoPrecise Antibodies. "IPA is pleased to collaborate with the Zymeworks team as we work together to treat COVID patients using our extensive, collective expertise."
Jennifer Bath, Ph.D., Chief Executive Officer of ImmunoPrecise, has reviewed and approved the scientific disclosure of this news release.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-CoV-2) at this time.
About the Azymetric™ Platform
The Azymetric platform enables the transformation of monospecific antibodies into bispecific and multispecific antibodies, allowing simultaneous binding to several different disease targets. This unique technology enables the development of multifunctional therapeutics that can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering and internalization, and increase tumor-specific targeting. These features are designed to enhance efficacy while reducing toxicities and the potential for drug resistance. Azymetric therapeutics have been engineered to retain the desirable drug-like qualities of naturally occurring antibodies, including low immunogenicity, long half-life and high stability. In addition, they are compatible with standard manufacturing processes that deliver high yields and purity, potentially reducing drug development costs and timelines.
About the EFECT™ Platform
The EFECT platform is a library of antibody Fc modifications engineered to activate or suppress the antibody-mediated immune response. This platform, which is compatible with traditional monoclonal as well as Azymetric bispecific antibodies, further enables the customization and optimization of therapeutic responses for different diseases.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks' second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks' proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.
About ImmunoPrecise Antibodies Ltd.
SOURCE: ImmunoPrecise Antibodies